Cargando…

The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy

Purpose The aim of the present study was to examine the predictive value of Return to Work Self-efficacy (RTWSE) on Return to Work (RTW) among employees undergoing chemotherapy for cancer and to examine the relative contribution of RTWSE as predictor variable compared to personal, health-related, il...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosbjerg, Rikke, Hansen, Dorte Gilså, Zachariae, Robert, Hoejris, Inger, Lund, Thomas, Labriola, Merete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716905/
https://www.ncbi.nlm.nih.gov/pubmed/32114672
http://dx.doi.org/10.1007/s10926-020-09882-2
_version_ 1783619250130255872
author Rosbjerg, Rikke
Hansen, Dorte Gilså
Zachariae, Robert
Hoejris, Inger
Lund, Thomas
Labriola, Merete
author_facet Rosbjerg, Rikke
Hansen, Dorte Gilså
Zachariae, Robert
Hoejris, Inger
Lund, Thomas
Labriola, Merete
author_sort Rosbjerg, Rikke
collection PubMed
description Purpose The aim of the present study was to examine the predictive value of Return to Work Self-efficacy (RTWSE) on Return to Work (RTW) among employees undergoing chemotherapy for cancer and to examine the relative contribution of RTWSE as predictor variable compared to personal, health-related, illness- and treatment-related and work-related factors. Methods A sample of 114 sickness absent employees with various cancers (age 18–62) included in the study on average 33 days after initiating chemotherapy were followed for 15 months. Data sources included patient questionnaires (RTWSE, depression, fatigue, performance status), sociodemographic factors (age, sex, job type, and perceived support from the workplace), patient records (type of cancer, treatment intention, number of treatment modalities, time since diagnosis and time since initiation of chemotherapy), and Danish national registries (RTW and education). Associations between RTWSE at baseline and weeks until full RTW during 15-months follow-up were analyzed using Cox proportional hazards regression. Results In the univariate analysis, high RTWSE was associated with shorter time to RTW (Hazard Ratio (HR) 1.84, 95% confidence interval (CI) 1.12–3.03). In the multivariate model, RTWSE failed to reach statistical significance (HR 1.12, 95% CI 0.62–2.02), whereas female sex (HR 0.30, 95% CI 0.15–0.60) and receiving palliative treatment (HR 0.15, 95% CI 0.05–0.44) were significantly associated with later RTW. Conclusion Compared to other factors of significance, RTWSE was not the strongest predictor of RTW when examined among employees undergoing chemotherapy for cancer. Before using the RTWSE questionnaire to identify employees with cancer at risk of late RTW, it is important to recognize that the predictive value of RTWSE may be different for employees on sick leave due to cancer than for other sickness absence populations.
format Online
Article
Text
id pubmed-7716905
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-77169052020-12-04 The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy Rosbjerg, Rikke Hansen, Dorte Gilså Zachariae, Robert Hoejris, Inger Lund, Thomas Labriola, Merete J Occup Rehabil Article Purpose The aim of the present study was to examine the predictive value of Return to Work Self-efficacy (RTWSE) on Return to Work (RTW) among employees undergoing chemotherapy for cancer and to examine the relative contribution of RTWSE as predictor variable compared to personal, health-related, illness- and treatment-related and work-related factors. Methods A sample of 114 sickness absent employees with various cancers (age 18–62) included in the study on average 33 days after initiating chemotherapy were followed for 15 months. Data sources included patient questionnaires (RTWSE, depression, fatigue, performance status), sociodemographic factors (age, sex, job type, and perceived support from the workplace), patient records (type of cancer, treatment intention, number of treatment modalities, time since diagnosis and time since initiation of chemotherapy), and Danish national registries (RTW and education). Associations between RTWSE at baseline and weeks until full RTW during 15-months follow-up were analyzed using Cox proportional hazards regression. Results In the univariate analysis, high RTWSE was associated with shorter time to RTW (Hazard Ratio (HR) 1.84, 95% confidence interval (CI) 1.12–3.03). In the multivariate model, RTWSE failed to reach statistical significance (HR 1.12, 95% CI 0.62–2.02), whereas female sex (HR 0.30, 95% CI 0.15–0.60) and receiving palliative treatment (HR 0.15, 95% CI 0.05–0.44) were significantly associated with later RTW. Conclusion Compared to other factors of significance, RTWSE was not the strongest predictor of RTW when examined among employees undergoing chemotherapy for cancer. Before using the RTWSE questionnaire to identify employees with cancer at risk of late RTW, it is important to recognize that the predictive value of RTWSE may be different for employees on sick leave due to cancer than for other sickness absence populations. Springer US 2020-02-29 2020 /pmc/articles/PMC7716905/ /pubmed/32114672 http://dx.doi.org/10.1007/s10926-020-09882-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Rosbjerg, Rikke
Hansen, Dorte Gilså
Zachariae, Robert
Hoejris, Inger
Lund, Thomas
Labriola, Merete
The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy
title The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy
title_full The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy
title_fullStr The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy
title_full_unstemmed The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy
title_short The Predictive Value of Return to Work Self-efficacy for Return to Work Among Employees with Cancer Undergoing Chemotherapy
title_sort predictive value of return to work self-efficacy for return to work among employees with cancer undergoing chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716905/
https://www.ncbi.nlm.nih.gov/pubmed/32114672
http://dx.doi.org/10.1007/s10926-020-09882-2
work_keys_str_mv AT rosbjergrikke thepredictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT hansendortegilsa thepredictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT zachariaerobert thepredictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT hoejrisinger thepredictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT lundthomas thepredictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT labriolamerete thepredictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT rosbjergrikke predictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT hansendortegilsa predictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT zachariaerobert predictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT hoejrisinger predictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT lundthomas predictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy
AT labriolamerete predictivevalueofreturntoworkselfefficacyforreturntoworkamongemployeeswithcancerundergoingchemotherapy